Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia

Aim: Ezetimibe is a novel cholesterol absorption inhibitor that reduces the level of low-density lipoprotein (LDL)-cholesterol (C). The effects of ezetimibe on remnant-like particle (RLP)-C, lipoprotein (a) [Lp(a)], and oxidized LDL (Ox-LDL) levels have not been examined. Methods: Fifty patients wit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Atherosclerosis and Thrombosis 2010, Vol.17(1), pp.37-44
Main Authors: Nozue, Tsuyoshi, Michishita, Ichiro, Mizuguchi, Ichiro
Format: Article
Language:English
Subjects:
Aged
Anticholesteremic Agents - administration & dosage
Azetidines - administration & dosage
C-Reactive Protein - metabolism
Cholesterol - blood
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Dyslipidemias - blood
Dyslipidemias - drug therapy
Ezetimibe
Female
Humans
Lipoprotein (a)
Lipoprotein(a) - blood
Lipoproteins - blood
Lipoproteins, LDL - blood
Male
Middle Aged
Oxidized low-density lipoprotein
Prospective Studies
Remnant-like particle cholesterol
Triglycerides - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: Ezetimibe is a novel cholesterol absorption inhibitor that reduces the level of low-density lipoprotein (LDL)-cholesterol (C). The effects of ezetimibe on remnant-like particle (RLP)-C, lipoprotein (a) [Lp(a)], and oxidized LDL (Ox-LDL) levels have not been examined. Methods: Fifty patients with dyslipidemia were treated with 10 mg/day of ezetimibe. At baseline and 12 weeks after treatment with ezetimibe, we measured the levels of RLP-C, Lp(a), Ox-LDL, and high-sensitivity C-reactive protein (hs-CRP). Results: The mean levels of total cholesterol (TC), LDL-C, triglycerides (TG), and apolipoprotein (apo) B, respectively, showed a significant decrease from 229±39 to 191±37 mg/dL (-16%, p
ISSN:1340-3478
1880-3873
DOI:10.5551/jat.1651